Related Experiment Videos
Early Termination of Phase II-III Genitourinary Oncology Trials: A Two-Decade Analysis of Causes and Trial-Level Risk
Kamil Malshy1, Jiacheng Wang2, Yusheng Jia3
1Department of Urology, University of Rochester Medical Center, Rochester, NY.
Purpose:
Early termination of clinical trials delays scientific progress and wastes resources, yet factors associated with trial completion in genitourinary (GU) oncology remain incompletely characterized. We investigated trial-level factors associated with premature discontinuation of phase II-III GU oncology clinical trials.
Materials And Methods:
We analyzed US phase II-III interventional GU oncology trials registered on ClinicalTrials.gov that were completed or terminated between January 1, 2005, and January 1, 2025. Prespecified operational and trial-level characteristics at initiation included disease site, phase, randomization, masking, sponsor type, number of sites, multinational status, data monitoring committee (DMC) presence, and intervention category. Reasons for early termination were categorized, and associations with premature discontinuation were assessed using multivariable logistic regression.
Results:
Among 1,597 trials, 445 (27.9%) were terminated early and 1,152 (72.1%) were completed. Poor accrual accounted for 41.8% of terminations, followed by sponsor or business decisions (14.6%) and interim futility or efficacy findings (10.3%). In multivariable analysis, prostate cancer trials were more likely to complete than bladder cancer trials (odds ratio [OR], 1.77, 95% CI, 1.25 to 2.50), as were multinational (OR, 1.96, 95% CI, 1.27 to 3.02) and multisite studies (OR, 1.72, 95% CI, 1.28 to 2.30). Trials enrolling metastatic-only (OR, 0.45, 95% CI, 0.29 to 0.72) or mixed-stage populations (OR, 0.55, 95% CI, 0.36 to 0.86), as well as those with DMC oversight (OR, 0.62, 95% CI, 0.47 to 0.81), were less likely to complete.
Conclusion:
More than one quarter of GU oncology trials terminate prematurely, most often due to accrual failure. Early termination is associated with identifiable disease-specific, structural, and operational trial characteristics. Recognition of these patterns may help inform feasibility assessment, trial planning, and resource allocation, with the goal of reducing preventable trial failure in GU oncology research.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Cancer Survival Analysis
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...